Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients

BACKGROUND: In the randomized, phase III, global SELECT-COMPARE study, upadacitinib 15 mg demonstrated efficacy at week 12 versus placebo and adalimumab with methotrexate (MTX) in patients with rheumatoid arthritis and inadequate response to MTX, which was maintained over 48 weeks. This post hoc ana...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Drugs Context
मुख्य लेखकों: Pavelka, Karel, Szekanecz, Zoltán, Damjanov, Nemanja, Anić, Branimir, Tomšič, Matija, Mazurov, Vadim, Maksimovic, Marija, Nagy, Orsolya, Świerkot, Jerzy, Petranova, Tzvetanka, Veldi, Tiina, Baranauskaitė, Asta, Codreanu, Catalin, Andersone, Daina, Fleischmann, Roy
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: BioExcel Publishing Ltd 2020
विषय:
Original Research
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7574850/
https://ncbi.nlm.nih.gov/pubmed/33123205
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.2020-7-5
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन